Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma

Shanghai, China, August 28, 2026 – Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating its transition from Biotech to Biopharma: CEVIRA®, the world’s first non-invasive treatment for precancerous cervical lesions, […] The post Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition